| Literature DB >> 16687945 |
Michael Doumas1, Stella Douma.
Abstract
The pharmacologic management of hypertension has long been implicated in the genesis of erectile dysfunction; the latter is considered the main reason of nonadherence to antihypertensive therapy. Older-generation antihypertensive drugs (central-acting, beta blockers, diuretics) negatively affect erectile function, while newer-generation agents (calcium antagonists, angiotensin-converting enzyme inhibitors) seem to have neutral effects. Preliminary data with the latest drugs (angiotensin receptor blockers) point to a beneficial effect on erectile function. Phosphodiesterase-5 inhibitors, used for the treatment of erectile dysfunction, can be safely and effectively administered to hypertensive patients (even when on multiple-agent antihypertensive therapy), with a caution regarding alpha blockers. In the case when erectile dysfunction is considered to result from antihypertensive therapy, the treating physician may either add phosphodiesterase-5 inhibitors or substitute current treatment with angiotensin receptor blockers.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16687945 PMCID: PMC8109585 DOI: 10.1111/j.1524-6175.2005.05285.x
Source DB: PubMed Journal: J Clin Hypertens (Greenwich) ISSN: 1524-6175 Impact factor: 3.738